Entera Bio Ltd.
ENTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $147.9M
$3.00
▲ +1.69%
P/E
39.11
Mkt Cap
$147.9M
52-Wk Range
$0.91–$4.20
52-Week Range
$0.91 - $4.20
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 50.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary oral delivery technology for large molecule therapeutics
- Strategic research collaboration and licensing agreement with Amgen Inc.
- Advanced clinical trial stage with multiple candidates in development
- Addressing unmet medical needs in large patient populations
Bear Case
1 risk
- Average volatility.
Growth
Profitability at risk
Advancement of EB612 through Phase II clinical trials for hypoparathyroidism
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+150.0% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ENTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 13, 2026
AUG 7, 2026
Reported EPS of -$0.14 vs -$0.08 consensus (-75.0% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-75.0%
Revenue trend · last 8Q
—
—
—
-100%
-100%
-100%
-100%
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$42.0K
$82.0K
$42.0K
$0
$0
$0
$0
$0
Margins · last 8Q
Profit
—
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jun 24, 2026
vs Industry
How ENTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related